|
Mechanismalpha-toxin inhibitors |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismImmunomodulators |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价AR-301作为抗生素的联合治疗用于金黄色葡萄球菌性呼吸机相关性肺炎(VAP)治疗的有效性和安全性的III期临床研究
[Translation] A Phase III clinical study to evaluate the efficacy and safety of AR-301 as a combination therapy with antibiotics for the treatment of Staphylococcus aureus ventilator-associated pneumonia (VAP)
主要临床有效性目的:评价单独SOC治疗与SOC+AR-301联合治疗在第21天临床治愈率方面的差异。已与该领域的临床专家共同确定了严格的临床治愈标准;主要临床安全性目的:旨在评估AR-301在研究人群中的临床安全性和耐受性。
[Translation] The main clinical efficacy objective is to evaluate the difference in clinical cure rate between SOC alone and SOC + AR-301 combination therapy on day 21. Strict clinical cure criteria have been jointly determined with clinical experts in this field; the main clinical safety objective is to evaluate the clinical safety and tolerability of AR-301 in the study population.
100 Clinical Results associated with Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd.
100 Deals associated with Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shenzhen Ruidi Bio-Pharmaceutical Co., Ltd.